Related references
Note: Only part of the references are listed.Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery
Tor Henrik A. Tvedt et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
Alexander Roeth et al.
HAEMATOLOGICA (2022)
Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
Mingkang Yao et al.
MEDICINE (2022)
O, wind, if winter comes ... will symptoms be far behind? Exploring the seasonality (or lack thereof) and management of cold agglutinin disease
Christopher J. Patriquin et al.
TRANSFUSION (2022)
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial
Georg Gelbenegger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Sutimlimab in patients with cold agglutinin disease results of the randomized placebo-controlled phase 3 CADENZA trial
Alexander Roeth et al.
BLOOD (2022)
IgM monoclonal gammopathies of clinical significance: diagnosis and management
Jahanzaib Khwaja et al.
HAEMATOLOGICA (2022)
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Sigbjorn Berentsen et al.
IMMUNOTHERAPY (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
Alexander Roeth et al.
ANNALS OF HEMATOLOGY (2022)
Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?
Sigbjorn Berentsen et al.
TRANSFUSION MEDICINE REVIEWS (2022)
Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
Alexander Roeth et al.
BLOOD (2022)
ARGX-117, a therapeutic complement inhibiting antibody targeting C2
Inge Van de Walle et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
How I treat cold agglutinin disease
Sigbjorn Berentsen
BLOOD (2021)
Autoimmune Hemolytic Anemias
Sigbjorn Berentsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease
Anna Zaninoni et al.
FRONTIERS IN IMMUNOLOGY (2021)
The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels
Agnieszka Malecka et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease
Lucia Perez-Lamas et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases
Robert Spiera et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sutimlimab in Cold Agglutinin Disease
Alexander Roeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center
Bruno Fattizzo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink et al.
BLOOD (2021)
Halting targeted and collateral damage to red blood cells by the complement system
M. Jalink et al.
SEMINARS IN IMMUNOPATHOLOGY (2021)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjorn Berentsen et al.
BLOOD (2020)
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjorn Berentsen
FRONTIERS IN IMMUNOLOGY (2020)
Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy
Oliver Tomkins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan
Toyomi Kamesaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program
Georg Gelbenegger et al.
BLOOD ADVANCES (2020)
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis
Catherine M. Broome et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Cold agglutinins: fending off the attack
Sigbjorn Berentsen
BLOOD (2019)
Next-generation Fc receptor-targeting biologics for autoimmune diseases
Adrian W. Zuercher et al.
AUTOIMMUNITY REVIEWS (2019)
Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition
Ferras Alashkar et al.
VACCINE (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
Novel insights into the treatment of complement-mediated hemolytic anemias
Sigbjorn Berentsen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Giuseppe Rossi et al.
BLOOD (2018)
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Johann Bartko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease
Sigbjorn Berentsen
SEMINARS IN HEMATOLOGY (2018)
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Alexander Roeth et al.
BLOOD ADVANCES (2018)
Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases
Janice A. Lansita et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2017)
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial
Jakob Muehlbacher et al.
TRANSPLANTATION (2017)
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study
M. Wahrmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity
Lucrezia Colonna et al.
CLINICAL IMMUNOLOGY (2016)
Complement An Overview for the Clinician
Juan Carlos Varela et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi et al.
BLOOD (2014)
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
Ulla Randen et al.
HAEMATOLOGICA (2014)
TNT009, a Classical Complement Pathway Specific Inhibitor, Prevents Complement Dependent Hemolysis Induced By Cold Agglutinin Disease Patient Autoantibodies
Sandip Panicker et al.
BLOOD (2013)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia
Sigbjorn Berentsen et al.
BLOOD REVIEWS (2012)
Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers
Vladimir Petrusic et al.
IMMUNOLOGIC RESEARCH (2011)
Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial
Jin-Shei Lai et al.
JOURNAL OF RHEUMATOLOGY (2011)
Classification and therapeutic approaches in autoimmune hemolytic anemia: an update
Marc Michel
EXPERT REVIEW OF HEMATOLOGY (2011)
Clinical immunology of chronic cold agglutinin disease
Elling Ulvestad et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Complete complement deficiency in a large cohort of familial systemic lupus erythematosus
R. Aggarwal et al.
LUPUS (2010)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Rituximab in chronic cold agglutinin disease:: a prospective study of 20 patients
C Schöllkopf et al.
LEUKEMIA & LYMPHOMA (2006)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Acute phase haemolysis in chronic cold agglutinin disease
E Ulvestad et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
Share Paper
